Home >> Signaling Pathways >> Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Products for  Apoptosis

  1. Cat.No. 产品名称 Information
  2. GC73441 EAPB 02303 EAPB 02303是一种微管破坏剂和抑制剂。
  3. GC73428 CWI1-2 hydrochloride CWI1-2 hydrochloride是一种结合IGF2BP2并抑制其与m6A修饰的靶转录物相互作用、诱导凋亡和分化的IGF2BP2抑制剂。
  4. GC73424 PRT062607 acetate

    P505-15 acetate; PRT-2607 acetate; BIIB-057 acetate

    PRT062607 acetate是一种口服Syk抑制剂(IC50: 1 nM),可抑制炎症和诱导细胞凋亡。
  5. GC73417 CASP8-IN-1 CASP8-IN-1(化合物63-R)是胱天蛋白酶8(CASP8)的选择性抑制剂,IC50为0.7μM。
  6. GC73396 PRMT6-IN-3 PRMT6-IN-3(化合物25)是一种选择性PRMT6抑制剂,IC50值为192 nM。
  7. GC73374 TD1092 TD1092是一种泛IAP降解剂,可降解cIAP1、cIAP2和XIAP。
  8. GC73372 (S)-Sabutoclax

    (S)-BI-97C1

    (S)-SabutoclaxS-BI-97C1是一种光学纯的棉酚衍生物,是抗凋亡B细胞淋巴瘤/白血病-2 Bcl-2家族蛋白的泛活性抑制剂。
  9. GC73371 Enpp/Carbonic anhydrase-IN-2 Enpp/Carbonic anhydrase-IN-2是一种强效的Enpp和碳酸酐酶抑制剂,NPP1、NPP2、NPP3、CA-IX、CA-XII的IC50分别为1.13、1.07、0.74、0.33、0.68。
  10. GC73355 STAT3-SH2 domain inhibitor 1 STAT3-SH2 domain inhibitor 1是STAT3(STAT3-SH2结构域)的强效Src同源2(SH2)结构域抑制剂,Kd值为1.57μM。
  11. GC73331 BMS-37 BMS-37是一种PD-1/PD-L1免疫检查点抑制剂。
  12. GC73317 ODN 1585 sodium ODN 1585 sodium是IFN和TNFα产生的强效诱导剂。
  13. GC73313 PI3Kα-IN-9 PI3Kα-IN-9(化合物27)是一种选择性、长效和口服活性的PI3Kα抑制剂,对PI3Kα、PI3Kγ、PI3Kδ和PI3Kβ的IC50值分别为4.4、128、146和153 nM。
  14. GC73311 STAT3-IN-13 STAT3-IN-13(化合物6f)是一种有效的STAT3抑制剂。
  15. GC73309 Anti-melanoma agent 1 Anti-melanoma agent 1(化合物5m)是一种抗黑色素瘤药物,可诱导细胞凋亡。
  16. GC73294 F5446 F5446(化合物1)是SUV39H1金属转移酶的选择性小分子抑制剂。
  17. GC73288 CDK8-IN-13 CDK8-IN-13是一种强效、选择性和口服活性的CDK8抑制剂,IC50值为51.9nM。
  18. GC73275 PD-L1-IN-2 PD-L1-IN-2是一种潜在的肿瘤免疫剂,通过抑制PD-L1。
  19. GC73274 EGFR T790M/L858R-IN-2 EGFR T790M/L858R-IN-2是一种有效的选择性EGFRT790M/L858R抑制剂,对EGFRT790M/L858R和EGFR WT的IC50值分别为3.5和1290 nM。
  20. GC73272 PARP-1-IN-3 PARP-1-IN-3苯甲酰胺衍生物是一种强效的PARP-1抑制剂,PARP-1和PARP-2的IC50值分别为0.25 nM和2.34 nM。
  21. GC73269 ABBV-467 ABBV-467是一种选择性MCL-1抑制剂(Ki: <0.01 nM)。
  22. GC73268 PH14 PH14是PI3K/HDAC双抑制剂,对PI3Kα和HDAC3的IC50值分别为20.3 nM和24.5 nM。
  23. GC73243 Nrf2-IN-3 Nrf2-IN-3(化合物R16)是一种Nrf2抑制剂。
  24. GC73237 BWA-522 BWA-522是一种口服小分子蛋白靶向嵌合体(PROTACs),对AR-FL和AR-V7具有显著的降解作用。
  25. GC73234 MY-673 MY-673是抑制微管蛋白聚合的秋水仙素结合位点抑制剂(CBSI)。
  26. GC73232 PRDX1-IN-1 PRDX1-IN-1是PRDX1的选择性抑制剂,IC50值为0.164μM。
  27. GC73228 MS78 MS78是乙酰化靶向嵌合体(AceTAC),其乙酰化p53肿瘤抑制蛋白。
  28. GC73225 ROS-generating agent 1 ROS-generating agent 1(化合物2c)共价修饰TrxR的Sec-498残基生成ROS。
  29. GC73220 LSD1-IN-24 LSD1-IN-24(化合物3S)是一种选择性LSD1抑制剂,IC50 = 0.247 μM。
  30. GC73212 TH-6 TH-6是一种强效的HDAC抑制剂,HDAC1、HDAC2、HDAC3、HDAC6、HDAC8的IC50分别为0.115、0.135、0.242、0.138、2.120µM。
  31. GC73210 MTR-106 MTR-106是一种强效的口服活性G-四链体稳定剂和RNA聚合酶I抑制剂。
  32. GC73199 M47 M47是一种小分子,选择性地破坏隐色素1 (CRY1)的稳定性,并增加细胞核中CRY1的降解。
  33. GC73188 SFI003 SFI003是一种SRSF3抑制剂,通过SRSF3/DHCR24/ROS轴驱动CRC细胞凋亡,在体外和体内均表现出强大的抗肿瘤作用。
  34. GC73168 p53 Activator 3 p53 Activator 3(化合物87A)是一种有效的p53激活剂,SC150值<0.05 mM。
  35. GC73166 U7D-1 U7D-1是一流的有效和选择性USP7(泛素特异性蛋白酶7)PROTAC降解剂,在RS4;11细胞中的DC50为33 nM。
  36. GC73159 KTX-582 KTX-582是一种有效的IRAK4降解剂,IRAK4和Ikaros的DC50值分别为4nM和5nM。
  37. GC73146 Sonrotoclax

    BGB 11417

    Sonrotoclax是一种有效的口服活性Bcl2抑制剂。
  38. GC73138 PBENZ-DBRMD PBENZ-DBRMD是一种强效的碘三碱脱碘酶3型(DIO3)抑制剂。
  39. GC73137 Nenocorilant NenocorilantKi值为0.15 nM的强效口服活性糖皮质激素受体(GR)拮抗剂。
  40. GC73136 VPC-70063 VPC-70063是一种强效的Myc-Max抑制剂,抑制Myc-Max转录活性的IC50值为8.9μM。
  41. GC73133 Misetionamide

    GP-2250

    Misetionamide是一种口服的类似恶硫嗪的化合物。
  42. GC73129 SIAIS164018 hydrochloride SIAIS164018 hydrochloride是一种基于protac的ALK和EGFR降解剂,ALK和ALK G1202R的IC50值分别为2.5 nM和6.6 nM。
  43. GC73118 EB1 EB1是MNK激酶的抑制剂,ic50值分别为0.69 μM (MNK1)和9.4 μM (MNK2)。
  44. GC73112 JPS014 TFA JPS014 TFA是一种基于苯甲酰胺的Von Hippel-Lindau(VHL)E3连接酶蛋白水解靶向嵌合体(PROTAC)。
  45. GC73109 Danvatirsen sodium

    AZD9150 sodium

    Danvatirsen sodium是一种靶向STAT3的反义寡核苷酸,具有潜在的抗肿瘤活性。
  46. GC73093 Custirsen sodium

    OGX-011 sodium

    Custirsen sodium抑制簇集蛋白的产生,簇集蛋白是一种抗凋亡蛋白,在化疗后上调,并赋予治疗耐药性。
  47. GC73077 ARI-1 ARI-1是受体酪氨酸激酶样孤儿受体1 (ROR1)抑制剂的抑制剂。
  48. GC73025 Teprasiran sodium

    QPI-1002 sodium

    Teprasiran sodium是一种小干扰RNA,可暂时抑制p53介导的细胞死亡,这是急性肾损伤(AKI)的基础。
  49. GC73016 AZD4877 AZD4877是Ispinesib的另一种同分异构体,也是一种激酶纺锤体蛋白(Eg5)抑制剂,IC50为2 nM。
  50. GC73002 Ganglioside GD3 diammonium Ganglioside GD3 diammonium是一种酸性鞘糖脂。
  51. GC72994 RAPTA-C

    Ru(Η6-p-cymene)Cl2(pta

    RAPTA-C (Ru(η - 6-p-cymene)Cl2(pta))是一种抗癌和抗血管生成剂。

Items 151 to 200 of 2733 total

per page
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6

Set Descending Direction